• Users Online: 252
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
Year : 2019  |  Volume : 4  |  Issue : 2  |  Page : 203-208

Risk factors of malignant portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma

1 Department of Internal Medicine, Assiut University Hospital, Assiut, Egypt
2 Department of Tropical Medicine and Gastroenterology, Aswan University Hospital, Aswan, Egypt
3 Department of Internal Medicine, Faculty of Medicine, Assiut University, Assiut, Egypt

Correspondence Address:
Abdallah A Abdelaal
Department of Internal Medicine, Faculty of Medicine, Assiut University, Assiut
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/JCMRP.JCMRP_23_19

Rights and Permissions

Introduction Hepatocellular carcinoma (HCC) is the sixth most commonly occurring cancer in the world and the second largest contributor to cancer mortality. In Egypt, liver cancer forms 11.75% of the malignancies of all digestive organs and 1.68% of the total malignancies. HCC constitutes 70.48% of all liver tumors among Egyptians. Malignant portal vein thrombosis (PVT) is a common phenomenon and is associated with poor prognosis. Knowing the risk factors of malignant PVT in HCC helps us in the management of the disease. Objective The objective of this study was to evaluate the risk factors of malignant PVT in cirrhotic patients with HCC. Patients and methods This was a case–control study that included 100 patients of HCC on top of liver cirrhosis. A total of 50 patients had HCC with malignant PVT, and the other 50 patients had HCC without malignant PVT, in the Internal Medicine department and Al-Raghy Liver Hospital between May 2016 and May 2017. Results This study showed that raised Model For End-stage Liver Disease score [odds ratio (OR)=1.34, 95% confidence interval (CI)=1.32–3.76; P = 0.02], low serum albumin (OR = 3.21, 95% CI = 2.11–3.21; P = 0.00) and raised α-fetoprotein (OR = 2.11, 95% CI = 1.09–4.11; P = 0.01) were independent predictors for malignant PVT in patients with HCC on top of liver cirrhosis. Conclusion High Model For End-stage Liver Disease score, low serum albumin and raised α-fetoprotein are major risk factors for malignant PVT in cirrhotic patients with HCC, and HCC with malignant PVT is associated with other comorbidities, high rates of hospital admission, larger tumor size and more recurrent tumors.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded64    
    Comments [Add]    

Recommend this journal